Breast cancer prevention by antihormones and other drugs: where do we stand?

Hematology/oncology clinics of North America ·Vol. 27 ·No. 4 ·2013-08-00 ·Pages 657-72, vii

Lazzeroni M, DeCensi A

Abstract

Breast cancer is the most common cancer in women worldwide. The selective estrogen-receptor (ER) modulators tamoxifen and raloxifene are approved by the Food and Drug Administration for the preventive therapy of breast cancer. Other drugs have shown promise but need further assessment. In the present review, we present an update of the chemoprevention of ER-positive breast cancer and discuss the potential role of metformin and aspirin, 2 drugs other than the specific "antihormones."

Keywords

Aromatase Inhibitors Aspirin Breast cancer chemoprevention Metformin Selective estrogen receptor modulators

MeSH Terms

Antineoplastic Agents/therapeutic use Antineoplastic Agents, Hormonal/therapeutic use Aromatase Inhibitors/therapeutic use Breast Neoplasms/drug therapy,prevention & control Female Humans Meta-Analysis as Topic Randomized Controlled Trials as Topic Selective Estrogen Receptor Modulators/therapeutic use

Chemicals

Antineoplastic Agents Antineoplastic Agents, Hormonal Aromatase Inhibitors Selective Estrogen Receptor Modulators

Authors & Affiliations

2 authors, click to expand affiliations / ORCID

Lazzeroni Matteo

Division of Cancer Prevention and Genetics, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy.

DeCensi Andrea

Article Info

Journal

Hematology/oncology clinics of North America

Abbr.

Hematol Oncol Clin North Am

ISSN

1558-1977

DOI

10.1016/j.hoc.2013.05.009

Published

2013-08-00

Pages

657-72, vii

Language

English

Region

United States

NLM ID

8709473

Subset

External Links

PubMed source DOI: 10.1016/j.hoc.2013.05.009 View journal details

Analysis Services

Breast cancer prevention by antihormones and other drugs: where do we stand?

Contact

WeChat Official Account